The novel Coronavirus Disease 2019 (COVID-19) appeared as an emerging respiratory disease in December 2019 in Wuhan, Hubei province, China, and then spread rapidly worldwide, being declared a pandemic on March 11, 2020. Researchers are attempting to discover specifically designed antiviral treatments for COVID-19. Several therapeutic agents such as Interferon-α, Lopinavir/Ritonavir, Ribavirin, Chloroquine, Chloroquine phosphate, Hydroxychloroquine, Arbidol, Favipiravir, Remdesivir, Darunavir, Imatinib, Teicoplanin, Azithromycin, COVID-19 convalescent plasma, other potential antiviral drugs, and Chinese herbal agents are now being clinically studied to examine both pharmaceutical efficacy and safety for COVID-19 treatment in several countries. Some favorable results from these studies have been obtained to date. This review article summarizes and reiterates drugs that are potentially efficient against COVID-19.
Tim Sandle has contributed to a new peer reviewed research paper:
Mohammadi M, Sandle T , Rajabi S, Khorshidi A, Piroozmand A. Potential Drugs for Treating COVID-19 Infection, Int J Infect. 7 (4) :e106243. doi: 10.5812/iji.106243
Scientists are endeavouring to find drugs to treat COVID-19. These attempts are currently focused on at least 30 drugs such as natural agents, Western drugs, and traditional Chinese therapeutic agents, each of which is potentially efficient against COVID-19. Clinical studies have been rapidly conducted on some of these agents, and the results are indicative of their initial efficacy against COVID-19.
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)